Healthtech & Wellness VC Funds

Arkitekt Ventures is a New York-based venture capital firm focused on advancing human health through early-stage investments. Their portfolio emphasizes innovative healthcare solutions, including digital health platforms, biotech, and frontier technologies like neurotech, AI, and bioengineering. Notable recent investments include Sollis Health, Nanite, and Mural Health, with check sizes ranging from $3M to $15M. Arkitekt primarily invests in the U.S. but has also backed companies in the UK, maintaining a sector focus in healthtech, medical devices, and life sciences. Their strategy centers on pre-seed to Series A stages, preferring startups with groundbreaking approaches to healthcare delivery and precision medicine. They rarely lead rounds but frequently co-invest with prominent partners like Bessemer Venture Partners and Torch Capital. Led by managing director Enke Bashllari and partner Pavan Choksi, Arkitekt Ventures values long-term partnerships and tends to back visionary founders who are leveraging cutting-edge science. Their team prefers a data-driven, relationship-building approach, and startups seeking funding should ideally present transformative technologies with strong early traction.

Arkley Brinc VC is a venture capital firm based in Warsaw, Poland, that focuses on early-stage investments in hardware-enabled startups, particularly in IoT, MedTech, and smart manufacturing sectors. The firm was established as a joint initiative between Arkley, a European pioneer in hardware investments, and Brinc, a global accelerator known for its deep connections in China’s manufacturing hubs. This partnership allows Arkley Brinc to offer startups not only capital but also a wealth of resources for product development, manufacturing, and global distribution. With a fund size of $15 million, Arkley Brinc invests up to $1 million per company, supporting them from the prototype stage through to IPO. The firm’s investments are concentrated in Poland and across Europe, leveraging its strategic networks to help startups scale effectively. Arkley Brinc has a strong track record, with over 50 projects supported and several successful exits and IPOs. The firm’s team consists of serial entrepreneurs and finance professionals with extensive experience in launching and scaling technology businesses. The Arkley Launchpad program is another key initiative, offering a highly individualized acceleration program designed to raise successful funding rounds and drive operational success. This program is tailored to the specific needs of each startup, providing access to a network of partners in prototyping, manufacturing, sales, and investment.

Armilar Venture Partners is a leading venture capital firm based in Lisbon, Portugal, with a strong international presence. Since its founding in 2000, Armilar has focused on early-stage technology-based companies, particularly in sectors where data, digitization, and connectivity are central. Notable investments include OutSystems, Feedzai, and Vawlt, showcasing their commitment to companies driving digital transformation. Armilar specializes in deep-tech investments, supporting startups that leverage cutting-edge technology to address significant societal challenges. They have a hands-on approach, providing not only capital but also strategic guidance to help their portfolio companies scale effectively. Their investment strategy includes focusing on companies with strong intellectual property and significant market potential, often leading funding rounds to ensure their startups have the resources needed for success. Geographically, while Armilar has a strong focus on Portugal, they are open to investing globally, demonstrating flexibility in finding and supporting the best opportunities regardless of location. Their investment strategy is characterized by patience and long-term support, often leading funding rounds and staying engaged through critical growth phases. The firm has a notable team, including Joaquim Rodrigues, the founder, and managing partners like Nuno Leite and Pedro Santos. These leaders bring extensive experience and a deep understanding of both technology and market dynamics, ensuring they can provide valuable support to their portfolio companies.

Arnold Venture Group is a Pacific Northwest-based venture capital firm that focuses on innovative companies across sectors like information technology, software, infrastructure, and business intelligence. Established in 2018, the firm invests in early to growth-stage companies, with check sizes ranging from $250K to $5M. Arnold Venture Group places a strong emphasis on companies with social impact, making strategic investments in the U.S. market. The firm has a diverse portfolio that includes sectors like media, healthcare, and food/agriculture. Notable investments include Videon Labs, AdaptX, and Picnic, demonstrating their wide-reaching impact across different industries. Arnold Venture Group typically co-invests alongside other well-known venture firms such as Voyager Capital and Vulcan, further enhancing its reach and network. Led by a small, experienced team, including partners Cole Younger and Robert Arnold, the firm supports its portfolio companies by leveraging deep industry knowledge and strategic connections. With its focus on scaling impactful companies, Arnold Venture Group continues to be a strong player in the venture capital ecosystem.

Array Ventures, founded in 2015 and based in San Francisco, focuses on early-stage investments in enterprise technology startups. The firm is led by Shruti Gandhi, who leverages her extensive background in software engineering and venture capital to support innovative companies. Array Ventures primarily invests in enterprise SaaS, data, AI, security, infrastructure, and cloud technologies. They typically invest between $250,000 to $2 million in pre-seed and seed rounds, aiming for 8-15% ownership in their portfolio companies. Notable investments by Array Ventures include Simility (acquired by PayPal), CasaOne, Blumira, MadStreet Den, Modal, and Uniform.dev. The firm has a strategic focus on founders with strong technical backgrounds who are leaving lucrative corporate jobs to tackle significant problems. They provide robust support to help these startups grow from initial stages to achieving significant ARR milestones. Array Ventures also has a global investment approach, backing companies that address worldwide markets, including notable investments in Indian and Israeli startups.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Arthur Ventures, established in 2008 and headquartered in Minneapolis, Minnesota, focuses on investing in early-stage B2B software companies across the U.S. and Canada. They emphasize backing startups located outside Silicon Valley, promoting innovation and growth in diverse regions. Arthur Ventures' portfolio includes a variety of successful companies. Notable investments feature DataCamp, an online data science training platform; Protenus, which offers patient data protection; and ThreatLocker, a zero-trust endpoint security solution. Other significant portfolio companies include Jane.app, a practice management software for health and wellness clinics, and CertifID, a network management software company. The firm has made over 102 investments and has seen 18 exits, with companies like Ionic and TINYpulse achieving successful outcomes. Arthur Ventures focuses on sectors such as SaaS, cybersecurity, fintech, and healthcare IT, providing capital and strategic support to help early-stage companies grow and succeed.

Artiman Ventures, founded in 2001, is a venture capital firm based in Silicon Valley with an additional office in Bangalore. The firm specializes in early-stage investments and adopts a "white space" investment strategy, focusing on sectors with little to no existing competition, thereby seeking to create or disrupt multi-billion dollar markets. Artiman is sector-agnostic and invests across a diverse range of industries including technology, medtech, and communications. Notable investments in Artiman's portfolio include companies like Virsec, which focuses on application security, and Visby Medical, which is revolutionizing disease diagnostics. Other significant investments include ApplyBoard, an AI-enabled marketplace for international students, and CellMax Life, a precision cancer blood-testing company. Geographically, Artiman primarily invests in companies based in the U.S. and India, leveraging its cross-border presence to help startups scale globally. Their investment strategy involves being the first institutional capital, often at the concept phase, and working closely with entrepreneurs to drive strategy, market definition, and execution​. The leadership team at Artiman includes experienced partners like Yatin Mundkur, Amit Shah, and Ajit Singh, who bring deep expertise in technology and life sciences investments. Founder Eric Benhamou, known for his tenure as CEO of 3Com and Palm, leads the team with a strong background in growing and managing tech companies.

ARTIS Ventures (AV) is a San Francisco-based venture capital firm founded in 2001 by Stuart Peterson, investing in category-defining companies at the intersection of technology, health, and biology. The firm coined and trademarked the term TechBio to describe this investment category, and has built one of the most distinctive track records in the space over more than two decades. Peterson is a Forbes Midas List honoree, recognized in large part for ARTIS's early bet on Stemcentrx. Additional partners include Austin Walne and Ameena El-Bibany. ARTIS leads rounds and deploys $250K to $25 million per investment — with a sweet spot around $10 million — at Seed and Series A stages across the United States, Canada, and Israel. With 84 investments to date, the portfolio spans YouTube, Palantir, Data Domain, Aruba Wireless Networks, Nimble Storage, Cohesity, Practice Fusion, Versa Networks, Excision BioTherapeutics, and Fabric Genomics. The firm invests across biotech, AI, software, health technology, and data analytics. ARTIS runs a structured TechBio Fellows program that embeds MDs, PhDs, and domain experts directly within the fund to work alongside the investment team and portfolio companies. This model bridges frontier science and venture investing in a concrete way: rather than relying on external advisors, the firm has built its own scientific talent pipeline inside the fund. The result is a portfolio company support infrastructure that is unusually deep for a venture firm of ARTIS's size.

Asahi Kasei Ventures — formally Asahi Kasei Corporate Venture Capital — is the CVC arm of Asahi Kasei Corporation, a diversified Japanese conglomerate with revenues exceeding $20 billion across its Materials, Homes, and Health Care divisions. Established in 2008 in Tokyo and operating from Silicon Valley since 2011, with additional offices in Menlo Park and Boston, the fund invests in innovative startups strategically aligned with Asahi Kasei's long-term business development. General Manager Takashi Morishita has guided the fund since inception, personally involved in investments in 30-plus startups. The firm has invested in 53-plus companies across the United States, Europe, China, and Japan, averaging two new investments annually. Checks range from $1 million to $10 million at seed through Series B stages. Focus areas include healthcare and digital health, advanced materials, IoT, clean technology, energy storage, hydrogen, and biopharmaceuticals. The most recent investment was in Glycomine at Series C in April 2025. The fund's Care for Earth investment framework extends the mandate to environmental startups in sustainability and carbon neutrality. Portfolio companies gain access to Asahi Kasei's extensive research capabilities, manufacturing infrastructure, and global commercial network — advantages that have resulted in multiple strategic collaborations and two acquisitions for the parent company. The fund's long-term orientation and corporate backing allow it to support companies through extended development cycles that financial-only investors may not sustain.

Ascension Ventures is a strategic healthcare-focused venture capital firm based in St. Louis, Missouri. Launched in 2001 by Ascension, it manages over $1 billion in assets across five funds. The firm strategically invests in early to late-stage companies within healthcare services, health technology, and medical devices. Its unique approach connects more than 450 healthcare providers, creating an ecosystem that enables startups to directly engage with health system executives, driving solutions that address complex healthcare challenges. Ascension Ventures’ portfolio includes companies like Olive (an AI platform for healthcare administration), EBR Systems, and GetWellNetwork, reflecting its emphasis on technology that enhances clinical outcomes, patient experience, and operational efficiency. The firm typically invests between Series A and B rounds, with capital sizes ranging from $10 to $20 million per company, often seeking board seats or observer rights to guide their portfolio firms. The firm is distinguished by its close ties to 13 major health systems, which represent a network of over 580,000 healthcare professionals. This strategic positioning allows Ascension Ventures not only to provide funding but also to facilitate partnerships and scale innovations that improve healthcare delivery across the United States.

Asha Impact, founded in 2014 by Vikram Gandhi and Pramod Bhasin, is an impact investment platform based in New Delhi. It focuses on sectors that address key social challenges in India, such as financial inclusion, education, healthcare, agriculture, and clean energy. By blending venture capital with philanthropy, Asha Impact supports early-stage companies that deliver scalable solutions to these pressing issues. The firm is known for backing startups like Adda247, an edtech platform, and Truemeds, a healthcare company providing affordable medicine. Asha Impact typically invests in early and growth-stage businesses, often alongside other prominent venture capital firms. The platform’s approach emphasizes creating sustainable impact while also generating strong financial returns, working closely with its portfolio companies to guide their growth. Asha Impact is committed to fostering a more equitable future by empowering businesses that contribute to social and economic progress across India and other emerging markets.

Asia Venture Group (AVG) is a Kuala Lumpur, Malaysia-based internet holding company and venture capital firm founded in 2013 by Tim Marbach and Kai Kux. With approximately $100 million in assets under management, AVG focuses on long-term value creation in Southeast Asian digital markets by launching and investing in scalable online business models. The firm is deliberately selective, taking hands-on operational roles rather than passive equity positions — functioning as an active company builder embedded in portfolio operations. AVG has made 35 investments primarily at pre-seed and seed stages across e-commerce, fintech, food and beverage, healthtech, and digital marketing. The portfolio includes one unicorn — Cars24 — alongside iMoney, TrustedCompany, KFit, HappyFresh, and Limitless Technology, with 16 portfolio acquisitions recorded. The firm leads rounds and writes checks of $500K to $5 million. Tim Marbach previously served as Executive Chairman of TrustedCompany; Kai Kux co-founded HappyFresh, giving the partners direct operating experience in portfolio-adjacent categories. AVG's company-builder model distinguishes it from financial-only venture investors in the region: the team combines international operational know-how with deep local market relationships and the ability to recruit and manage local management talent on behalf of portfolio companies. This hands-on approach is particularly valuable in Southeast Asia, where market dynamics vary significantly by country and local execution is often the decisive competitive factor.

Asimov Ventures is an early-stage venture capital firm with offices in New York City and Palo Alto. The firm focuses on investing in cutting-edge technologies such as 3D printing, robotics, and advanced computing. Asimov Ventures seeks to partner with visionary entrepreneurs dedicated to transforming their industries through innovative solutions. Notable investments by Asimov Ventures include Particle3D, which specializes in 3D-printed bone implants, and Kadena, a blockchain technology company. The firm also invests in various other sectors, including healthcare, e-commerce, and augmented reality, reflecting their broad interest in transformative technologies​. Asimov Ventures typically participates in funding rounds with other notable investors, providing capital and strategic support to help startups scale and succeed. Their investment strategy emphasizes early-stage companies with strong intellectual property and commercial potential​.

Aspect Ventures, founded in 2014 by Jennifer Fonstad and Theresia Gouw, is a leading venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments, primarily in Series A rounds, across various sectors including cybersecurity, fintech, digital health, and enterprise software. Notable investments include Gusto, a cloud-based HR management platform; Chime, a digital bank; and Exabeam, a cybersecurity company. Aspect Ventures has had several successful exits such as Forescout Technologies, Imperva, and Trulia.

Asset Management Ventures (AMV) is a Palo Alto-based venture capital firm founded in 1965 by Pitch Johnson, one of Amgen's co-founders — making it one of the longest continuously operating VC firms in Silicon Valley. The firm specializes in early-stage investments in digital health, technology, and life sciences, and raised its fifth and largest fund at $150 million in 2020. Partners Skip Fleshman and Lou Lange lead the current investment team, which combines scientific, engineering, and medical expertise with decades of investing experience. With 152 investments and 29 exits, AMV's historical portfolio includes Amgen itself, Tandem Computer, and Applied BioSystems — foundational companies in their respective industries. The current portfolio includes Reify Health, Evidation Health, Lark, Twist Bioscience (TWST), Freenome, Welldoc, ViewPoint Therapeutics, Aavia, and 3T Biosciences, reflecting AMV's sustained focus on health technology and life sciences innovation. The firm leads rounds and deploys $1 million to $15 million across seed through Series B stages. AMV's six-decade track record is its most distinctive asset: the firm has seen multiple complete technology and healthcare cycles, giving the investment team a depth of pattern recognition and investor network that newer funds cannot replicate. The founding connection to Amgen also provides an ongoing cultural orientation toward building enduring life sciences companies rather than optimizing for short-cycle exits — an orientation that informs how AMV partners with founders over the long arc of company development.

Astanor Ventures, founded in 2017 by Eric Archambeau and George Coelho, is a Brussels-based venture capital firm specializing in sustainable agrifood technologies. The firm focuses on investing in early-stage, mission-driven companies that address significant social or environmental issues within the agrifood value chain. This includes sectors like regenerative agriculture, bioeconomy, and climate-positive solutions. Astanor recently closed its second venture fund at €360 million, bringing its total assets under management to €800 million. This fund will support innovative solutions aimed at transforming the global food system to be more sustainable and resilient​. The firm boasts an extensive network of entrepreneurs, experts, scientists, and policymakers, which helps identify and nurture groundbreaking technologies. Notable investments include companies that advance autonomous electric agricultural machinery, high-functioning proteins, and genomic sequencing for sustainable food production.

Astarc Ventures, established in 2015, is the corporate venture arm of Astarc Group based in Mumbai, India. The fund focuses on early-stage investments in innovative technology companies across various sectors, including fintech, healthtech, logistics, AI/ML, and e-commerce. Notably, Astarc Ventures invests globally, with a presence in markets like India, Israel, the United States, and the United Kingdom. The firm typically supports entrepreneurs whose ventures align with Astarc Group's strategic interests and disruptive technologies. With over 60 investments, Astarc Ventures has backed companies such as Rooter, Purple Style Labs, Jai Kisan, and Dataloop. These investments span diverse industries from AI-driven solutions to consumer marketplaces and climate-tech. The firm is also known for its exits, including Liv.ai, which was acquired by Flipkart in 2018. Led by Executive Director Salil Musale and an experienced team, Astarc Ventures leverages deep operational expertise to help portfolio companies scale. The team takes an active role in guiding startups, offering both strategic advice and operational support, especially in emerging sectors.

Astarte Ventures is a Yardley, Pennsylvania-based venture capital fund founded in 2013 by Tracy Warren, recognized as the first venture fund dedicated exclusively to the health and wellbeing of women and children. As a first-mover in FemTech investing — well before the category had a name — Warren built a concentrated portfolio anchored in early intervention and prevention, spanning healthtech, life sciences, and technology sectors that improve outcomes for mothers, women, and children. Warren also serves as a mentor at Harvard's Wyss Institute. The fund has made eight investments at seed and Series A stages with checks of $500K to $3 million. Two outcomes define the portfolio's credibility: Maven Clinic, which became the largest virtual clinic for women's and family health and achieved unicorn status in 2021, and Alydia Health, acquired by Organon for $215 million in March 2021. These exits anchor the fund's FemTech track record against a backdrop of concentrated, conviction-led investing. Astarte Ventures' small portfolio size is intentional — Warren's model prioritizes deep engagement with each company over broad deployment. Each portfolio company benefits from Tracy Warren's domain expertise in female health outcomes and impact investing, as well as her network across academic medicine, women's health advocacy, and the broader healthcare industry. For founders in FemTech, backing from Astarte carries the credibility of the category's earliest and most dedicated institutional champion.

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma, one of the world's leading pharmaceutical companies. Founded in 2005 and headquartered in South San Francisco, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies for over twenty years. The investment thesis is explicitly strategic: AVM targets science that enhances the Astellas R&D pipeline or catalyzes new directions in discovery research, with the team's Pharma View serving as both a selection lens and a support framework. AVM has invested in 61 companies across 104 total investment rounds, deploying $3 million to $20 million per company at seed through Series B stages. Series A is the most active stage, with 19 investments averaging $33.8 million in round size. Notable current portfolio companies include Solu Therapeutics, Syntax Bio, PhoreMost, and Somite. The most recent investment was in Solu Therapeutics in April 2025, and the most recent exit was Orna Therapeutics in February 2026. A team of eight, including three partners and one principal, spans the US and Japan. AVM's principal value to portfolio companies is its deep pharmaceutical industry expertise and the pathway it opens to Astellas Pharma: strategic licensing dialogues, research collaborations, and potential acquisitions that purely financial investors cannot facilitate. For early-stage biotech founders, AVM's Pharma View means receiving guidance from investors who understand drug development not as outsiders but as participants in the global pharmaceutical system.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Astutia Ventures is a Munich, Germany-based venture capital firm founded in 2006 by Benedict Rodenstock, focused on innovative European startups across three thematic areas: smart cities, the future of commerce, and digital lifestyle. The firm invests at seed and Series A stages, writing checks of $500K to $3 million, with a portfolio of 30 companies built over nearly two decades of active European investing. The team of four, including two partners, operates alongside an advisory practice — Astutia Advisory — that extends the firm's influence into venture capital consulting. Portfolio companies include Commercetools, a modern commerce infrastructure platform; Mister Spex, a leading European eyewear e-commerce company; Dreamlines, a cruise booking platform; Koloma, an energy company; and 99chairs, an interior design marketplace. The firm frequently co-invests with HTGF (High-Tech Gründerfonds) and other established European early-stage funds, indicating its position within the core Munich and broader German venture network. Astutia's thematic focus on smart cities, commerce, and lifestyle technology has proven durable over multiple market cycles, covering both consumer-facing and enterprise applications within European markets. Benedict Rodenstock's Munich business network gives portfolio companies access to the Bavarian industrial and commercial ecosystem — a geography that is both one of Europe's most economically productive and one of the less saturated by venture capital compared to Berlin or London. The firm's selective approach and deep regional roots produce a portfolio that is distinctive rather than generic.

Asymmetric Financial is a venture capital firm that focuses on investing in early-stage companies within the fintech, software, and digital health sectors. Founded by Joe McCann in 2022, the firm operates with a unique approach to venture capital, combining deep expertise in technology and finance to support companies that are poised to disrupt traditional industries. Asymmetric Financial aims to identify and back innovative startups that leverage advanced technologies such as artificial intelligence, blockchain, and big data analytics to create new market opportunities. The firm’s investment strategy is centered on providing not only capital but also strategic guidance and operational support. Asymmetric Financial works closely with its portfolio companies to help them scale efficiently, offering assistance in areas such as financial planning, go-to-market strategies, and key performance indicator (KPI) development. This hands-on approach ensures that the startups in their portfolio are well-equipped to navigate the challenges of rapid growth and market competition. Asymmetric Financial is particularly interested in companies that have the potential to generate significant returns while also creating meaningful impact through their innovations. By focusing on sectors that are at the intersection of technology and finance, the firm aims to contribute to the modernization and transformation of the financial services industry.

Asymmetric Capital Partners (ACP) is a venture capital firm focused on backing B2B technology companies from Seed to Series C stages. Founded in 2020 by Rob Biederman, former co-CEO of Catalant Technologies, ACP manages an oversubscribed debut fund of $105 million. The firm targets disruptive businesses in areas like healthcare IT, fintech, marketplaces, and next-gen software, especially those transforming legacy industries and capitalizing on digital innovation. ACP is known for its hands-on approach, leveraging a team of founders and former operators who work closely with startups on strategic growth areas such as hiring, go-to-market strategies, and financial planning. They typically invest between $2M to $10M, with the flexibility to co-invest in larger deals alongside top firms like Andreessen Horowitz and Sequoia Capital. Some notable investments include Firstbase, a remote work platform backed by Andreessen Horowitz, and Clearco, a fintech company. The firm prides itself on being deeply involved with its portfolio companies, providing both operational support and access to a vast network of advisors and industry experts.

Asymmetry Ventures, based in San Francisco, is a prominent early-stage venture capital firm founded by Rob Ness. The firm focuses on investing in transformative startups that have the potential to create significant impact. They have a diverse portfolio of over 280 investments, including notable companies like BillionToOne, Foresight Mental Health, Mast Reforestation (formerly DroneSeed), and Orbit Fab. Asymmetry Ventures is known for their commitment to supporting defensible businesses, particularly in sectors such as artificial intelligence, biotechnology, and aerospace. They typically make initial investments in the range of $2 million and have been involved in notable funding rounds such as Orbit Fab's $10 million raise, which also saw participation from major aerospace players like Northrop Grumman and Lockheed Martin. The firm prides itself on identifying and backing visionary founders and innovative business models, with a strong emphasis on early-stage investments that leverage technology to create natural barriers to entry and generate recurring revenue streams. They also prioritize investments that address significant market needs with scalable solutions. For startups looking to partner with Asymmetry Ventures, demonstrating a strong leadership team and a clear path to market dominance are crucial. The firm's deep network and extensive industry experience provide valuable support and guidance to their portfolio companies, enhancing their potential for growth and success.

AT Inc, now known as Amazon Catalytic Capital, is Amazon’s venture capital initiative with an initial commitment of $150 million aimed at supporting underrepresented founders. The fund invests in venture capital funds, accelerators, incubators, and venture studios that prioritize startups led by Black, Latino, Indigenous, women, and LGBTQIA+ entrepreneurs. This initiative not only provides financial backing but also offers mentorship from Amazon executives and access to resources that can aid in business and technical strategy. Key investments include Collide Capital, Elevate Future Fund, Share Ventures, and Techstars Rising Stars Fund. These funds focus on diverse founders working in areas such as clean energy, fintech, health tech, and consumer goods. Amazon’s goal is to foster inclusion and innovation, ultimately driving economic growth and creating generational wealth for historically underserved communities.

At One Ventures is a venture capital firm founded in 2020 by Tom Chi, a founding member of Google X. The firm is dedicated to investing in early-stage startups that are developing disruptive deep tech solutions aimed at making humanity a net positive to nature. With a strong focus on climate tech, At One Ventures has established itself as a significant player in the industry. The firm recently closed its second fund at $375 million, indicating strong investor confidence and a robust commitment to supporting climate-positive innovations. This fund follows their initial $150 million fund and aims to support startups that can dramatically reduce environmental footprints while upending established industrial economics. At One Ventures' investment portfolio includes companies across various sectors such as renewable energy, sustainable agriculture, and advanced materials. Notable investments include Noon Energy, which focuses on long-duration energy storage, and MightyFly, which is developing hybrid electric drone delivery systems. The firm's approach is hands-on, providing strategic guidance in talent acquisition, operations, marketing, IP strategy, and manufacturing. The team at At One Ventures consists of experienced professionals with backgrounds in physical sciences, engineering, manufacturing, and finance, ensuring a deep understanding of the technologies and markets they invest in. They operate globally, with a presence in San Francisco and London, and continue to seek partnerships with entrepreneurs, scientists, and investors who share their vision for a sustainable future.

at.inc/, originally founded in 2015 as Tank Hill Ventures, is a boutique seed-stage venture capital firm that partners with founders 'at incorporation,' backing startups at the earliest possible stage, sometimes as early as the idea phase, then providing continuity, capital and support throughout the venture journey. Operating across Silicon Valley and Israel, the firm leads seed rounds with conviction and concentrates on technology startups with disruptive business models, with top sectors in enterprise applications and enterprise infrastructure. Geographically its portfolio skews to the United States, around 60%, Israel, around 20%, and the United Kingdom, around 20%. The firm is led by Managing Partner Nadav Eylath, who has led seed investments in Netlify, Wescover, Disclosures.io, HoneyBook, Future Family, Opendoor (IPO) and Peer5 (acquired by Microsoft); General Partner Roni Bonjack brings operating experience having built and led global startup programs for Google and Facebook. After its first fund reportedly returned over 10x, the firm raised an oversubscribed $35M Fund II under the at.inc/ brand. By its own account it has made 58 investments with 12 exits, one IPO and four unicorns, including Netlify, HoneyBook and Placer.ai. Notable recent deals include leading Bagel AI's $5.5M seed in April 2025, a $3.0M seed in Podqi in March 2025, HelloCity's $585K pre-seed in 2024 and Stack's seed round in 2024. Early signature wins include leading Netlify's $2.1M seed in 2016 alongside the founders of GitHub, Heroku and Rackspace. at.inc/ specializes in being the very first institutional partner to technical founders.

Ataraxia VC is a global venture capital firm managing multiple funds, including the Social Starts and Joyance Partners funds, which focus on early-stage investments in health, happiness, and well-being. Ataraxia typically operates at the pre-seed and seed stages, with follow-on investments up to Series A. They target sectors like biotech, neuroscience, precision health, femtech, and next-gen food technologies. Their portfolio includes over 250 companies globally, with a strong focus on science-driven, transformative opportunities. The firm's strategy emphasizes investments in innovative companies that align with its vision of improving health and happiness through technology. With funds spread across the US and Europe, Ataraxia provides both capital and strategic guidance to help startups scale rapidly. They prioritize founders with groundbreaking solutions, especially in consumer tech, wellness, and sustainability-focused sectors. Key team members include Mike Edelhart, a seasoned investor with decades of experience, and Holly Jacobus, an investment partner with a focus on femtech, farmtech, and sustainable manufacturing. Ataraxia’s approach is hands-on, often providing mentorship and guidance through every stage of a startup’s journey​.

Ataria Ventures is a Peru-based venture capital firm founded in 2017 by Managing Partners Alejandro Ponce and JP Ortiz, headquartered in San Isidro, Lima. The firm serves as a structured gateway for Latin American investors and corporations to engage with the world's leading technology ecosystems, combining direct venture investment with corporate venture building. It has completed more than 50 deals, with a direct portfolio of 15-plus companies and a broader network of over 40 companies worldwide. Ataria invests primarily at seed and Series A stages, with checks ranging from $100,000 to $2 million, across artificial intelligence, big data, agritech, foodtech, consumer, and health sectors in Latin America and the United States. Notable portfolio companies include Beam and GoTrendier. The founding partners bring backgrounds in venture investing, private equity, and digital transformation — a combination that positions the firm to bridge Latin American capital with global technology opportunities. The firm's core differentiation is its Corporate Venture Capital and Venture Building model, which offers Latin American corporates a structured pathway into startup innovation without building in-house venture teams from scratch. By combining investment with co-creation of digital businesses, Ataria helps established corporations participate meaningfully in the technology ecosystem while providing portfolio founders with access to corporate distribution channels and regional scale.

Atelier Ventures, founded by Li Jin, is an early-stage venture capital firm focused on the "Passion Economy," a concept that promotes enabling individuals to monetize their unique talents, creativity, and knowledge. This shift reflects the growing trend of people transitioning away from traditional employment toward independent work that aligns with their personal passions. Li Jin, who previously worked at Andreessen Horowitz, launched Atelier Ventures to fund companies that help democratize access to entrepreneurship. The firm’s investment thesis revolves around empowering creators by providing them with the tools, platforms, and resources to turn their individuality into income. Atelier Ventures supports startups building solutions that reduce the barriers to entry for entrepreneurship, including fintech platforms, SaaS tools, and educational services. These platforms facilitate the creation, distribution, and monetization of content, whether through podcasting, e-commerce, or other creative fields. Atelier Ventures focuses on businesses that promote independence while fostering community and collaboration among creators. Atelier’s portfolio includes companies that are reshaping the future of work by making it easier for creators to build and scale businesses. The firm envisions a future where creators, freelancers, and solopreneurs can collaborate in trusted networks and thrive in the digital age. This vision aligns with Li Jin's mission to support founders who challenge the status quo and create new, fulfilling work opportunities in the evolving digital landscape.

Atento Capital is a Tulsa-based venture capital firm founded with the mission of supporting early-stage tech startups, particularly those in underinvested communities. The firm was launched with backing from the George Kaiser Family Foundation, focusing on generating both market returns and social impact by funding innovative companies in the Heartland region of the U.S. Atento primarily invests in seed and early-stage companies, with check sizes ranging from $250,000 to $3 million. They are committed to fostering diversity in entrepreneurship, directing nearly half of their capital to underrepresented founders, including women and founders of color. Notable portfolio companies include RobbieAI, a platform using computer vision to prevent patient injuries, and PatchRx, a health tech solution aimed at improving medication adherence​. Beyond funding, Atento provides hands-on support to startups by offering mentorship, business development guidance, and access to local talent via partnerships with organizations like inTulsa. Their approach is deeply rooted in building long-term success for founders who have traditionally been overlooked by the broader venture capital ecosystem.

Atinum Investment, the venture capital arm of Atinum Partners, is a prominent South Korean investment firm with over $450 million in assets under management. The firm focuses on diverse sectors such as deep tech, artificial intelligence, blockchain, advanced robotics, bio-healthcare, and IT components. They actively invest in early-stage to growth-stage startups with significant global market potential. Notable portfolio companies include CryptoQuant, Allganize, and Klook. Atinum Investment has a global reach, particularly focusing on Southeast Asia, with investments in companies like InstaReM and Fast Five, a South Korean co-working space startup. The team at Atinum Investment includes key figures such as Wan Gee Cho, who specializes in deep tech and SaaS investments, and Peter Na, the Regional Head for Southeast Asia, focusing on investments in the region from the Singapore office. Atinum is committed to providing more than just capital by offering strategic guidance and opening doors to potential customers and partners, ensuring the growth and success of their portfolio companies.

Atlantic Bridge, founded in 2004, is a global growth equity technology firm that focuses on investing in deep technology companies across Europe, the UK, and the US. With over €1 billion in assets under management, the firm has a portfolio of 70 companies and has created over 5,000 jobs. Atlantic Bridge is known for its cross-border value-add strategy, helping portfolio companies expand internationally through its offices in Dublin, London, Munich, Paris, and Palo Alto. The firm's portfolio includes notable companies such as SOC Prime, which specializes in enterprise threat detection and response, and Elisity, which combines Zero Trust Network Access with an AI-enabled Software Defined Perimeter. Other significant investments include Siren, an investigative intelligence platform, and Aizon, which optimizes pharmaceutical manufacturing processes using real-time data and predictive models. Atlantic Bridge has achieved successful exits with companies like Navitas Semiconductor, which recently debuted its GaN Power ICs on Nasdaq, and Mitiga, a provider of hybrid managed services for incident response and readiness. The firm is led by experienced industry professionals, including Managing Partners Elaine Coughlan, Brian Long, and Kevin Dillon, who bring extensive expertise in scaling technology companies and executing successful IPOs and M&As.

FoodLabs, founded in 2015 and based in Berlin, Germany, is a prominent venture capital firm dedicated to investing in innovative startups within the food, health, and sustainability sectors. The firm supports companies aiming to revolutionize how we produce, consume, and think about food, with a mission to create sustainable and healthy solutions for the future. FoodLabs has made a significant impact with its diverse portfolio, which includes companies like ChefCoco, a personalized weekly menu service, and Van Heron Labs, which focuses on biotechnology. The firm has been an early investor in some of the most influential European FoodTech startups, such as Infarm, Meatable, Mushlabs, and Sanity Group. These investments span across various stages, from pre-seed to series B and beyond, demonstrating FoodLabs' commitment to nurturing startups through their growth journey. The team at FoodLabs, led by founder Christophe Maire and managing director Patrick Noller, combines deep industry expertise with a strong network to provide strategic support and resources to their portfolio companies. They are particularly focused on sectors like synthetic biology, climate resilience, and health, aiming to address some of the world's most pressing challenges.

Atlantic Labs, based in Berlin, is a prominent early-stage venture capital firm that supports mission-driven founders across Europe. Founded in 2013, the firm has a focus on investing in transformative technology sectors such as climate tech, digital health, future of work, AI and data, industrial automation, mobility and logistics, fintech, and proptech. Atlantic Labs typically invests at the pre-seed stage, with investment sizes ranging from €25,000 to €5 million or more. They have backed over 215 companies, including notable names like SoundCloud, GetYourGuide, Clue, Vimcar, and Cazoo. The firm emphasizes a hands-on approach, providing not only capital but also strategic guidance and access to a robust network of industry experts to help their portfolio companies grow and succeed. The firm's portfolio reflects its diverse focus areas, supporting companies that aim to redefine various industries through innovative solutions. Examples include digital health companies like Clue, AI and data startups such as Mobius Labs, and mobility ventures like GetYourGuide and Cazoo. Atlantic Labs is led by a team of experienced investors and operators who are committed to supporting entrepreneurs throughout their entire journey. This commitment to fostering innovation and growth has established Atlantic Labs as a key player in the European venture capital landscape.

Atlantic Vantage Point (AVP), based in Paris, is an independent global investment platform with more than $2.7 billion in assets under management. Originally founded in 2016 as the corporate venture capital arm of AXA — one of the world's largest insurance groups — the firm completed a management buyout from AXA in 2024 to become a fully independent entity, with AXA remaining as an anchor limited partner. AVP leads rounds across Europe and North America, deploying from its flagship €1.5 billion AVP Growth I fund. The firm has made 94 investments across enterprise software, fintech, insurtech, digital health, and cybersecurity, backing businesses from early growth through to late stage. With typical checks ranging from $10 million to $100 million, AVP operates as a transatlantic platform combining deep local expertise in both European and North American markets. Its heritage in insurance and financial services provides portfolio companies with a distinctive strategic lens and access to industry relationships built over years within the AXA ecosystem. AVP's investment approach emphasizes strategic guidance alongside capital, leveraging its position at the intersection of European and US technology markets to help portfolio companies scale across both geographies. The firm's scale, sector expertise, and ability to support companies across multiple funding rounds distinguish it from single-geography growth investors. Its 2024 independence marks a new phase — one defined by broader LP relationships while retaining the institutional depth of its AXA origins.

Atlas Venture is a leading biotech venture capital firm focused on creating and building innovative life science companies. With over 30 years of experience, they have incubated over 70 startups and taken 40 companies public, including Intellia Therapeutics, Kymera Therapeutics, and Generation Bio. Atlas specializes in drug discovery and development, emphasizing areas like gene editing, oncology, and immunotherapy. Headquartered in Cambridge, Massachusetts, Atlas primarily targets U.S.-based startups but maintains a global vision, partnering with top scientific minds. They invest early, often leading seed and Series A rounds, with typical check sizes ranging from $5M to $20M. Atlas's approach is hands-on, actively incubating new ventures and co-founding companies with a strong operational focus. Key figures include Jean-François Formela, who has been instrumental in several high-profile exits and IPOs, and focuses on cutting-edge drug discovery technologies. Founders approaching Atlas should focus on breakthrough science with clear therapeutic applications, as the firm seeks to translate groundbreaking research into life-changing medicines.

Atlas Venture is a leading venture capital firm specializing in early-stage investments in biotechnology and life sciences. Founded in 1980 and based in Cambridge, Massachusetts, Atlas Venture has built a robust portfolio by focusing on groundbreaking biotech innovations. The firm has raised multiple funds, including their most recent Fund XIII at $450 million, which emphasizes their commitment to fueling biotech startups from seed stage through to successful exits​. Notable investments in their portfolio include companies like Intellia Therapeutics, Kymera Therapeutics, and Ikena Oncology. These investments highlight Atlas Venture's dedication to developing therapies that address significant unmet medical needs, particularly in oncology and genetic disorders. Intellia Therapeutics, for instance, is renowned for its gene-editing technologies, while Kymera Therapeutics focuses on protein degradation to treat diseases. Atlas Venture has achieved numerous successful exits, such as the acquisitions of IFM Therapeutics by Bristol-Myers Squibb and Novartis, and the IPO of Generation Bio. These exits underscore the firm’s strategic capability in identifying and nurturing high-potential biotech startups to maturity. The firm is led by a team of experienced partners, including Jean-Francois Formela, Jason Rhodes, and David Grayzel, who bring a wealth of expertise in venture capital and life sciences. This team collaborates closely with entrepreneurs to provide not just capital but also strategic guidance and operational support, leveraging their extensive network within the biotech industry. For startups aiming to partner with Atlas Venture, it is crucial to present innovative solutions with strong scientific foundations and clear pathways to address significant medical challenges. The firm values startups that demonstrate potential for substantial clinical impact and scalability within the healthcare sector.

AtmosClear Investments is a Lausanne-based venture capital firm dedicated to accelerating the clean-tech revolution by investing in disruptive technologies that drive sustainability. Established in 2001, AtmosClear focuses on sectors like renewable energy, water purification, sustainable agriculture, and smart city infrastructure. Their diverse portfolio includes companies working on innovative solutions such as large-scale solar and wind energy projects, energy storage, recycling systems, and biofuels, with investments across Europe, particularly the UK and Switzerland. One of their notable ventures is Close the Loop, a recycling company specializing in repurposing ink cartridges, and they have also managed major solar installations in the UK, totaling over 30 MW. The firm’s mission is to generate both financial returns and positive environmental impact, emphasizing the reduction of harmful pollutants like microplastics and greenhouse gases. They support companies at various stages, from early startups to more mature businesses in need of growth capital​. AtmosClear’s team is led by experienced professionals with decades of expertise in finance and private markets. Founder Henry Sykes and his team leverage their deep knowledge to identify opportunities that align with their sustainability ethos. The firm’s global reach is underscored by investments in multiple continents, and they continue to seek out promising clean-tech entrepreneurs who share their vision of a more sustainable future. With a strong emphasis on long-term ecological benefits, AtmosClear is setting a new standard for responsible, impactful investing in the clean-tech space.

Atomico, founded in 2006 by Skype co-founder Niklas Zennström, is a leading venture capital firm based in London, with additional offices in Paris, Berlin, and Stockholm. The firm focuses on Series A and beyond investments in disruptive technology companies globally. Atomico's notable investments include Klarna, Truecaller, Lime, Hinge Health, and Rovio, which highlight their strong presence in fintech, healthcare, consumer tech, and gaming sectors. Atomico's investment strategy centers around partnering with mission-driven European founders, providing them with not just capital but also extensive operational support through their Growth Acceleration Team. This team assists with scaling operations, strategic planning, and navigating complex market dynamics. Their typical investment range is from $10 million to $50 million, and they often lead rounds, ensuring significant influence in their portfolio companies' trajectories. The firm is known for its diverse team and deep industry expertise. Key figures include Niklas Zennström, CEO and Partner; Chris Barnes, COO; and Thomas Wehmeier, Partner and Head of Insights, all based in London. This diverse leadership team brings a wealth of experience from various sectors, enhancing their ability to support and scale innovative startups. For startups looking to engage with Atomico, it's crucial to showcase innovative solutions with a potential for significant market impact. The firm is particularly interested in technology-driven companies that can leverage shifts in consumer behavior and technological advancements.

ATP Fund, established in 2014 and headquartered in Austin, Texas, is an early-stage venture capital firm that focuses on deep tech investments aimed at advancing human conditions through scientific innovation. The firm specializes in sectors such as artificial intelligence (AI), biotechnology, cleantech, cybersecurity, enterprise software, healthcare, and robotics. ATP Fund is known for its strategic investments in startups that are tackling some of the most challenging and impactful problems of our time. ATP Fund adopts a contrarian and hands-on approach, often partnering with scientific entrepreneurs at the earliest stages of their ventures, sometimes even at the formation stage via their Proto.n initiative. This strategy reflects their commitment to long-term partnerships and their belief in the transformative potential of cutting-edge technologies. The fund's portfolio includes a variety of high-impact companies like Diligent Robotics, which focuses on healthcare robotics, and Infleqtion, a firm that specializes in quantum technology. These investments highlight ATP Fund's dedication to supporting ventures that have the potential to make significant advancements in their respective fields. ATP Fund collaborates with a wide network of co-investors, including notable names like Texas Venture Labs and Osage University Partners. The firm has also seen successful exits, further establishing its reputation as a key player in the deep tech investment landscape.

Atria Ventures is a San Francisco-based venture capital firm founded in 2023 by General Partner Chris Leiter. The firm invests at the intersection of life sciences and artificial intelligence, partnering with founders working at the edges of biology and human health to reimagine the trillion-dollar life sciences industry from molecule to patient. Atria leads rounds at pre-seed and seed stages, with a sweet spot of $800,000 and a range of $250,000 to $2 million. Through its closed Fund I, Atria has made 15 investments across healthcare AI, biotech, and clinical development. Notable portfolio companies include Sleuth Insights in healthcare analytics, Peer AI in healthcare artificial intelligence, and Trially in clinical trials technology. The most recent investment was in Peer AI's Series A in October 2025, reflecting the firm's commitment to following its strongest portfolio companies into later rounds. Atria differentiates itself through singular focus on the convergence of computational approaches and life sciences — a sector where AI is fundamentally transforming drug discovery, diagnostics, clinical trials, and patient care delivery. Rather than investing broadly across healthcare, the firm concentrates on companies where deep learning, biological data, and clinical insight create compounding advantages. Chris Leiter's background informs a hands-on, thesis-driven approach that prioritizes founders working on problems with both scientific novelty and clear paths to clinical or commercial adoption.

Augment Ventures is a venture capital firm based in Ann Arbor, Michigan, specializing in early-stage investments across North America. The firm, founded in 2011 by Sonali Vijayavargiya, focuses on companies at the intersection of digital innovation and data utilization, particularly in sectors such as supply chain, fintech, industry 4.0, health tech, proptech, climate tech, B2B, and SaaS​. Notable investments by Augment Ventures include companies like LLamasoft, which was sold to Coupa Software for $1.5 billion, Optilogic, a cloud-native supply chain software solution, and Fluree, a platform recognized among the coolest data management companies​. Their portfolio also features innovative companies like Pair Team, Secro, Guardhat, and Crowdz, which span diverse industries from healthcare and fintech to supply chain and industrial safety. Augment Ventures emphasizes partnering with mission-oriented founders and diverse teams to address significant, real-world challenges. They provide not just capital but also strategic guidance and operational support to help startups scale and succeed in a constantly evolving global economy​.

August Capital is a venture capital firm founded in 1995, with a focus on backing innovative startups, primarily in the information technology sector. Based in Silicon Valley, August Capital has over $2 billion under management, making investments from early-stage startups to later-stage companies with high-growth potential. The firm has a strong track record of investing in transformative businesses like Splunk, Bill.com, and Atheros, helping entrepreneurs grow and scale their companies​. Unlike many venture capital firms, August Capital prides itself on taking a more personal approach to investing. They choose to work with fewer companies to provide more hands-on support. This includes helping founders with crucial aspects like talent recruitment, funding strategies, and customer acquisition. Their philosophy is that entrepreneurship is a team sport, and they aim to serve as a valuable resource for companies as they navigate the complexities of building successful ventures​. The team at August Capital includes highly experienced investors with deep networks and expertise across various tech sectors, making them well-positioned to support startups from inception through to potential exits. Their focus on early-stage investments allows them to nurture groundbreaking ideas and transform them into industry leaders.

Auriga Partners is a Paris-based venture capital firm established in 1998. The firm specializes in early-stage investments across various sectors, including information technology, life sciences, and cybersecurity. Auriga Partners has a strong focus on supporting high-potential ventures in Europe, North America, and Israel. Notable investments by Auriga Partners include Vade Secure, Nexthink, and Exeliom Biosciences. Vade Secure, a leader in predictive email defense, and Nexthink, a prominent analytics software provider, highlight Auriga’s commitment to backing innovative tech companies. Exeliom Biosciences, a biotech firm focused on the development of microbiome therapeutics, demonstrates their investment in life sciences. Auriga Partners has a robust portfolio with over 171 investments and 77 exits, reflecting their extensive experience and successful track record in venture capital. Their approach involves not only providing capital but also leveraging their expertise and network to support the growth and development of their portfolio companies. The team at Auriga Partners includes seasoned professionals like Philippe Granger, Mathieu Chatain, and Nabil Gharios, who bring significant industry knowledge and investment experience.

Aurum Ventures M.K.I is a Ramat Gan, Israel-based growth capital firm founded in 2005 as the venture capital vehicle of Morris Kahn, the prominent Israeli businessman and philanthropist who served as former chairman of Amdocs. The firm provides value-added capital to exceptional entrepreneurs in life sciences and clean technology, investing primarily at Series A, B, and later stages in companies with demonstrated clinical or commercial traction. Aurum has invested in 15 companies across biotech, clean tech, health technology, and pharma, with notable portfolio companies including LifeBond, Nephera, and BPT. The firm leads rounds with checks typically between $3 million and $20 million. Over its history, 55 co-investors have participated in Aurum's portfolio companies, including institutional names such as TELUS Ventures, RA Capital Management, and BlackRock — a reflection of the caliber of deal flow the firm sources. Aurum Ventures' core competitive advantage is the network, credibility, and industry relationships that come with the backing of Morris Kahn — one of Israel's most respected business leaders. Portfolio companies benefit from strategic guidance grounded in decades of operating and investing experience in the Israeli and global technology landscape. The firm's focus on life sciences and clean tech positions it at the intersection of two sectors where Israel has developed notable scientific and engineering depth, and where patient, relationship-driven capital creates meaningful differentiation at growth stage.

Authentic Ventures is a venture capital firm based in Oakland, California, focused on seed and early-stage investments. Founded in 2016 by Lindsay Lee JD, the firm targets a diverse range of industries, including enterprise software, consumer products, digital health, and deep tech sectors. Authentic Ventures emphasizes the importance of diversity and inclusivity, actively seeking to support women and minority founders who are tackling significant problems. The firm manages a concentrated portfolio, making 4-6 new investments annually, and works closely with its portfolio companies to ensure their success. Some notable investments include Verbal, Humans Anonymous, and Credit Mountain, highlighting their commitment to innovation and impactful solutions across various sectors. Authentic Ventures' team comprises experienced professionals, including Robin Bordoli, Amel Abdelwahid, and Michael Nichols JD, who collectively bring deep expertise in finance, compliance, and operations. The firm leverages a robust network to provide startups with the resources and connections needed to thrive.

Auxxo is a Berlin-based venture capital firm launched in 2019, specifically focused on driving diversity in venture capital by investing in female-founded startups. Its Female Catalyst Fund, led by Gesa Miczaika and Bettine Schmitz, aims to support pre-seed and seed-stage companies across Europe with at least one female co-founder. With a strong commitment to gender equity, Auxxo invests in a broad range of sectors including health care, fintech, biotech, and sustainability, often partnering with other VCs and family offices. Auxxo typically invests between €100k and €600k per round, positioning itself as a co-investor rather than a lead investor, and has built a portfolio of companies like Filu, Fermify, and Ubimaster. Auxxo has gained recognition for its mission to close the gender gap in VC, while empowering female entrepreneurs with strategic support and access to networks.